Wells Fargo & Company Aprea Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APRE
# of Institutions
2Shares Held
899Call Options Held
0Put Options Held
0About Aprea Therapeutics, Inc.
- Ticker APRE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Description
- Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...